International Patent: N-(6-CHLOROPYRIDIN-3-YL)-6-METHOXY-NICOTINAMIDE DERIVATIVES AND ANALOGUES THEREOF AS POTENTIATORS OF KV7.2 AND KV7.3 VOLTAGE-GATED POTASSIUM CHANNELS FOR TREATMENT OF SEIZURE, DEPRESSION, PAIN OR ANHEDONIA

GENEVA, July 2 -- XENON PHARMACEUTICALS INC. filed a patent application (US2025/060591) for “N-(6-CHLOROPYRIDIN-3-YL)-6-METHOXY-NICOTINAMIDE DERIVATIVES AND ANALOGUES THEREOF AS POTENTIATORS OF KV7.2 AND KV7.3 VOLTAGE-GATED POTASSIUM CHANNELS FOR TREATMENT OF SEIZURE, DEPRESSION, PAIN OR ANHEDONIA”. With publication no. WO/2026/136834, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07D 401/12

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....